©2022 Stanford Medicine
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Trial ID: NCT02396862
The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A
- Age 16 or over.
- Have documentation of physician-confirmed diagnosis of moderate or severe Hemophilia A
(severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity
- Signed written informed consent provided by the patient or the patient's parents for
patients under the age of 18 (dependent of local regulations).
- Signed written assent is also required for patients under the age 18 years (dependent
on local regulations).
- Plan to receive at least half of their Hemophilia care at the registry site.
- Willing and able to enter data as per the data collection schedule.
- Currently receiving prophylactic or on demand treatment (including within last 6months
for on demand).
- Expected life expectancy of at least 2 years.
- Patients with Hemophilia B
- Patients with von Willebrand disease (vWD)
- Patients with other rare bleeding disorders
- Unable to comply with the study protocol
drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
School of Medicine
300 Pasteur Drive
Stanford, CA 94305